Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Study of Atezolizumab Plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects With Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab

NCT05168163 is registered in ClinicalTrials.gov with Academic and Community Cancer Research United as lead sponsor.

NCT NCT05168163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05168163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Study of Atezolizumab Plus Multi-Kinase Inhibitor Versus Multi-Kinase Inhibitor Alone in Subjects With Unresectable, Advanced Hepatocellular Carcinoma Who Previously Received Atezolizumab Plus Bevacizumab
Lead sponsor
Academic and Community Cancer Research United
Phase
Phase 2
Overall status
Recruiting
Start date
May 27, 2022
Completion date
December 31, 2026
Enrollment
122 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced hepatocellular carcinoma, metastatic hepatocellular carcinoma, stage iii hepatocellular carcinoma ajcc v8, stage iiia hepatocellular carcinoma ajcc v8, stage iiib hepatocellular carcinoma ajcc v8, stage iv hepatocellular carcinoma ajcc v8, stage iva hepatocellular carcinoma ajcc v8, stage ivb hepatocellular carcinoma ajcc v8, unresectable hepatocellular carcinoma